Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma

Completed · Phase 2

Conditions studied: Sarcoma

In brief

The purpose of this study is to determine the overall best tumor response rate to dacarbazine given until disease progression as assessed by RECIST criteria, CT and clinical exams in patients with metastatic sarcomas.

Key facts

Study ID
NCT00802880
Run by
Washington University School of Medicine
People needed
80
Starts
2009-03-01
Expected to finish
2015-01-01
Last updated by the study team
2017-02-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.